OFIX News & Events

Nasdaq and S&P 500 futures are higher as chip stocks rebound after recent weakness. The Dow also enters the week near record territory. Markets are returning from the holiday weekend with a constructive tone, as investors look to extend last week's rally and begin the new week.Last week's weaker-than-expected labor report reduced some fears of additional near-term Federal Reserve tightening, which has helped improve risk appetite. Investors are now turning attention to Wednesday's Fed meeting minutes for clues on how policymakers view inflation and economic growth going into the second half of the year.Earnings season also begins to move into focus this week. Investors are looking for confirmation that corporate earnings can continue justifying elevated valuations after a strong first half of 2026. Analysts are expecting more than 20% year-over-year earnings growth for S&P 500 companies.In pre-market trading, S&P 500 futures rose 0.41%, Nasdaq futures rose 1.17% and Dow futures fell 0.07%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Seerup 37% after receiving an unsolicited, non-binding proposal from Omid Farokhzad, Seer's chair and CEO, to acquire all of the outstanding shares of Seer's Class A common stock for $2.45 per share in cash plus two separate contingent value rightsTeraWulfup 17% after executing a 20-year lease agreement with Anthropic at its Justified Data campus in Hawesville, KentuckyOrthofixup 6% after disclosing that CMS had reversed itself on its very recent 10% reimbursement cut within traditional Medicare for non-invasive bone growth stimulatorsBroadcomup 4% after disclosing an agreement with Appleto expand their long-standing technology collaboration through 2031 by entering into new multi-year long-term agreements for Broadcom to develop and supply a range of custom ASIC silicon products for use in multiple generations of Apple productsKosmosup 3% after providing a portfolio updateOpus Geneticsup 3% after reaching alignment with the FDA in a Type B Rare Disease Evidence Principles meeting on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5Comcastup 1% after announcing Sky has agreed terms to acquire ITV Media & Entertainment from ITV plc for a total consideration of up to GBP 1.6BAlibabaup 1% after BloombergU.S. District Judge Eumi Lee has ordered the Pentagon to give Alibaba reprieve from a law that led to many lobbyists dropping it as a client while she considers the constitutionality of the measureLOWER -Datadogdown 4% after Bernstein downgraded the stock to Market PerformJ.B. Huntdown 1% after Morgan Stanley downgraded shares to Underweight

In a regulatory filing on Friday, Orthofix stated: "On April 16, 2026, the U.S. Food and Drug Administration issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare & Medicaid Services modified certain billing requirements and Medicare fee schedule treatment applicable to non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. On July 1, 2026, CMS issued revised guidance that withdrew those changes and directed that Devices furnished on or after May 18, 2026 be processed and paid consistent with the treatment in effect prior to the FDA reclassification. Based on these developments, Orthofix Medical currently expects average Medicare reimbursement for these codes will return to the rates in effect prior to May 18, 2026."